KO

Kura Oncology

Organization

Heard in 3 episodes across 3 shows since Dec 2025

Kura Oncology, Inc. is a biopharmaceutical company developing precision medicines for cancer, including therapies targeting genetically defined tumors.

Episodes

3
across 3 shows

First heard

Dec 2025

Expert statements

6
5 positive · 1 negative

Episodes per month

Public PodLume episodes featuring it, over the last year.

Show the data
MonthEpisodes
Dec 20251
Jan 20260
Feb 20260
Mar 20260
Apr 20260
May 20260
Jun 20260
Jul 20260
Aug 20260
Sep 20260
Oct 20260
Nov 20262

Email alert

Email me when Kura Oncology comes up on a podcast

One email a week at most, with the new episodes that mention Kura Oncology. Free, no account needed, unsubscribe in one click.

What experts have said about Kura Oncology

6 statements · 5 positive · 1 negative

  1. Jim CramerPositiveDec 20, 2025· Mad Money w/ Jim Cramer

    A major Cura breakthrough would produce substantial stock gains.

    “If Cara makes a big breakthrough, you're going to see huge gains.”

    Listen at 22:20

    Open the episode · Mad Money w/ Jim Cramer 12/19/25
  2. Jim CramerNegativeDec 20, 2025· Mad Money w/ Jim Cramer

    Cura Oncology could suffer severe losses after failed results or setbacks.

    “If it doesn't or if there are setbacks, it will be eviscerated”

    Listen at 22:23

    Open the episode · Mad Money w/ Jim Cramer 12/19/25
  3. Jim CramerPositiveDec 20, 2025· Mad Money w/ Jim Cramer

    Broader leukemia approval could expand Cura’s drug market to $5–$10 billion.

    “Right now, this drug is approved for one type of disease. That's a $350 to $500 million end market. But if it gets approved for every type of acute leukemia, well, then you know what? That's a $5 to $10 billion market.”

    Listen at 26:06

    Open the episode · Mad Money w/ Jim Cramer 12/19/25

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

3 episodes featuring Kura Oncology, newest first